Carlos Amaya-Chanaga, MDPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Five Years of Follow-Up from the Phase 3 RESONATE-2 Study
Jillian Settlemire, RN, Edythe M. Greenberg, PhD, RN, FNP-BC, Indu Lal, MD, Carlos Amaya-Chanaga, MD, Jan A. Burger, MD, PhD, Steven Coutre, MD
November 13, 2020 | November 2020 Vol 11, No 11
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
Last modified: November 13, 2020